Quantcast

Latest National Institute on Drug Abuse Stories

2010-09-22 06:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule. This...

2010-09-22 06:00:00

ST. JOSEPH, Mich., Sept. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal. The SBIR grant will be used to develop a database and systems biology tool-set specifically designed for the study of the...

2010-09-20 22:35:07

Drug created by UCI, Italian team inhibits enzyme that breaks down anandamide American and Italian researchers have found that a novel drug allows anandamide "“ a marijuana-like chemical in the body "“ to effectively control pain at the site of an injury. Led by Daniele Piomelli, the Louise Turner Arnold Chair in Neurosciences and director of the Center for Drug Discovery at UC Irvine, the study suggests that such compounds could form the basis of pain medications that don't...

2010-09-14 01:08:09

Selected awardee studies the mechanisms of latent HIV infection to develop counter measures aimed at eliminating the virus The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced today that Dr. Eric M. Verdin of the J. David Gladstone Institutes in San Francisco, Calif., has been selected as the 2010 recipient of the NIDA Avant-Garde Award for HIV/AIDS Research for his proposal to study the mechanisms of latent HIV infection. NIDA's annual Avant-Garde...

2010-08-16 14:25:09

Findings represent additional clues to help predict vulnerability to drug abuse A regulatory protein best known for its role in a rare genetic brain disorder also may play a critical role in cocaine addiction, according to a recent study in rats, funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study was published today in the journal Nature Neuroscience. Researchers at the Scripps Research Institute in Jupiter, Fla. found that...

2010-08-03 06:00:00

SOUTH SAN FRANCISCO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule. This placebo and active controlled Phase 3 study is being conducted at 21 sites...

2010-07-09 13:48:04

Discovery could lead to better ways of predicting drug abuse risk and treating addictions A specific and remarkably small fragment of RNA appears to protect rats against cocaine addiction - and may also protect humans, according to a recent study funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study was published today in the journal Nature. RNA (ribonucleic acid) molecules are known to play critical roles in the translation of...

17fdcf1c022a81bf22a226b7ef21fa031
2010-04-20 06:45:00

While ecstasy became infamous as a drug taken at night clubs or during parties, new research suggests that it might help those suffering from post-traumatic stress disorder (PTSD). Ecstasy, also known as methylenedioxymethamphetamine (MDMA), was outlawed by the Drug Enforcement Agency (DEA) in 1985. However, researchers led by South Carolina psychiatrist Dr. Michael Mithoefer, found that the drug helped PTSD patients overcome their symptoms. Mithoefer conducted a study involving 20 patients,...

2010-04-13 09:49:00

CORAL GABLES, Fla., April 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies...

2010-03-15 14:55:00

Normal individuals who scored high on a measure of impulsive/antisocial traits display a hypersensitive brain reward system, according to a brain imaging study by researchers at Vanderbilt University. The findings provide the first evidence of differences in the brain's reward system that may underlie vulnerability to what's typically referred to as psychopathy. The study in the current issue of the journal Nature Neuroscience was funded by the National Institute on Drug Abuse (NIDA), a...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related